# US 2023/0390193 A1 · Gastroretentive pharmaceutical dosage form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390193 A1
- Document ID: US20230390193A1
- Status: Published application
- Kind: A1
- Application number: 18/250,754
- Filed: 2021-10-29
- Published: 2023-12-07
- Earliest claimed: 2020-10-30
- Assignees: Triastek, Inc.
- Applicants: Triastek, Inc.
- Inventors: Feihuang DENG; Yu ZHENG; Juan YAO; Xiaoling LI; Senping CHENG; Xianghao ZUO
- Web page: https://patentgrep.com/patent/US20230390193A1

## CPC

- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4883: {Capsule finishing, e.g. dyeing, aromatising, polishing}
- A61M 31/00: Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008})
- B33Y 80/00: Products made by additive manufacturing
- A61J 3/06: into the form of pills, lozenges or dragees
- B29C 64/118: using filamentary material being melted, e.g. fused deposition modelling [FDM]
- B33Y 10/00: Processes of additive manufacturing
- B33Y 70/00: Materials specially adapted for additive manufacturing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)

## Abstract

A pharmaceutical dosage form, comprising: a pharmaceutical unit which includes a drug, at least one unfolding member, and a retaining member, wherein the unfolding member is connected to the pharmaceutical unit, and is constructed to have a contracted shape, which makes the unfolding member become closer the pharmaceutical unit, and an unfolding shape, which makes the unfolding member become farther away from the pharmaceutical unit; the retaining member is connected to the at least one unfolding member, and applies a constraint force to the at least one unfolding member, so as to make the unfolding member be in the contracted shape; and the retaining member contains a water-soluble material, and is constructed to remove the constraint force from the unfolding member when the water-soluble material is dissolved, such that the at least one unfolding member can change from the contracted shape to the unfolding shape.

## Claims

### Claim 1

A pharmaceutical dosage form, comprising:
a pharmaceutical unit comprising a drug;
at least one unfolding member connected to the pharmaceutical unit and configured to have a contracted shape proximal to the pharmaceutical unit and an unfolding shape distal to the pharmaceutical unit; and
a retaining member connected to the at least one unfolding member and applying a constraint force to the at least one unfolding member to enable the unfolding member to be in the contracted shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the unfolding member when the water-soluble material is dissolved, such that the at least one unfolding member can change from the contracted shape to the unfolding shape.

### Claim 2 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the unfolding member comprises at least one elastic portion configured such that the unfolding member is in the contracted shape proximal to the pharmaceutical unit under the action of the constraint force, and returns to the unfolding shape distal to the pharmaceutical unit when the constraint force is withdrawn.

### Claim 3 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the retaining member at least partially encases the pharmaceutical unit and the at least one unfolding member, such that the at least one unfolding member is in the contracted shape.

### Claim 4 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the retaining member is disposed between the pharmaceutical unit and the unfolding member and is connected to the pharmaceutical unit, such that the unfolding member is in the contracted shape.

### Claim 5 (depends on 1)

The pharmaceutical dosage form according to claim 1, comprising a plurality of unfolding members, wherein the retaining member is connected to at least two unfolding members, such that the at least two unfolding members are in the contracted shape.

### Claim 6 (depends on 2)

The pharmaceutical dosage form according to claim 2, wherein the elastic portion is located at one end of the unfolding member adjacent to the pharmaceutical unit.

### Claim 7 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the unfolding member has a portion with reduced thickness at the end adjacent to the pharmaceutical unit.

### Claim 8 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the unfolding member has a strip, petal, or rod shape.

### Claim 9 (depends on 1)

The pharmaceutical dosage form according to claim 1, comprising a plurality of unfolding members substantially uniformly distributed along the periphery of the pharmaceutical unit.

### Claim 10 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the pharmaceutical unit comprises a hollow compartment.

### Claim 11 (depends on 1)

The pharmaceutical dosage form according to claim 1, wherein the pharmaceutical unit comprises an outer shell and a drug-containing inner core, wherein the outer shell comprises the same host material as the unfolding member.

### Claim 12

A method for preparing a pharmaceutical dosage form using a three-dimensional printing process, comprising:
printing a pharmaceutical unit and an unfolding member layer by layer, such that the unfolding member is connected to the pharmaceutical unit;
configuring the unfolding member to have a contracted shape proximal to the pharmaceutical unit from an unfolding shape; and
directly printing a retaining member, such that the retaining member is connected to at least one unfolding member and applies a constraint force to the at least one unfolding member to enable the unfolding member to be in the contracted shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the unfolding member when the water-soluble material is dissolved, such that the at least one unfolding member can change from the contracted shape to the unfolding shape.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the at least one unfolding member is printed to comprise at least one elastic portion configured such that the unfolding member is in the contracted shape proximal to the pharmaceutical unit under the action of the constraint force, and returns to the unfolding shape distal to the pharmaceutical unit when the constraint force is withdrawn.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the printing the retaining member comprises:
printing the retaining member, such that the retaining member at least partially encases or bonds with the pharmaceutical unit and the at least one unfolding member, such that the at least one unfolding member is in the contracted shape.

### Claim 15 (depends on 12)

The method according to claim 12, wherein the printing the retaining member comprises:
printing the retaining member, such that the retaining member is disposed between the pharmaceutical unit and the unfolding member and is connected to the pharmaceutical unit, such that the unfolding member is in the contracted shape.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the steps of printing the at least one unfolding member and printing the retaining member are performed simultaneously or alternately by different print heads.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the unfolding member is printed to have a portion with reduced thickness at one end adjacent to the pharmaceutical unit.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the printing the at least one unfolding member comprises:
printing the at least one unfolding member in the unfolding shape; and
moving the at least one unfolding member, such that the unfolding member is in the contracted shape.

### Claim 19 (depends on 12)

The method according to claim 12, wherein the pharmaceutical unit comprises a first portion comprising a drug and a second portion comprising no drug, wherein the first portion comprising the drug is printed after the step of printing the retaining member is completed.

### Claim 20

A pharmaceutical dosage form, comprising:
a pharmaceutical unit comprising an outer shell layer and a drug layer, wherein at least a portion of the pharmaceutical unit has a bent or folded shape; and
a retaining member connected to the pharmaceutical unit and applying a constraint force to the pharmaceutical unit to enable at least a portion of the pharmaceutical unit to retain the bent or folded shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the pharmaceutical unit when the water-soluble material is dissolved, thereby allowing at least a portion of the pharmaceutical unit to unfold from the bent or folded shape.

### Claim 21 (depends on 20)

The pharmaceutical dosage form according to claim 20, wherein the pharmaceutical unit is configured to have a helical shape with a radius of curvature gradually increasing from the inside to the outside, and the retaining member at least partially fills a gap of the helical shape of the pharmaceutical unit.

### Claim 22 (depends on 20)

The pharmaceutical dosage form according to claim 20, wherein the pharmaceutical unit comprises the outer shell layer and the drug layer, wherein the outer shell layer is composed of a hydrophobic material.

### Claim 23 (depends on 22)

The pharmaceutical dosage form according to claim 22, wherein the drug layer comprises a hydrophilic material.

### Claim 24 (depends on 23)

The pharmaceutical dosage form according to claim 23, wherein the drug layer comprises a first portion and a second portion, wherein the first portion and the second portion comprise different drugs.

### Claim 25 (depends on 20)

The pharmaceutical dosage form according to claim 20, wherein the pharmaceutical unit is generally in an elongated shape when unfolded.

### Claim 26

A method for preparing a pharmaceutical dosage form using a three-dimensional printing process, comprising:
printing a pharmaceutical unit comprising a drug, such that at least a portion of the pharmaceutical unit has a bent or folded shape; and
printing a retaining member, such that the retaining member is connected to the pharmaceutical unit and applies a constraint force to the pharmaceutical unit to enable at least a portion of the pharmaceutical unit to retain the bent or folded shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the pharmaceutical unit when the water-soluble material is dissolved, thereby allowing at least a portion of the pharmaceutical unit to unfold from the bent or folded shape.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the pharmaceutical unit is configured to have a helical shape with a radius of curvature gradually increasing from the inside to the outside, and the retaining member at least partially fills a gap of the helical shape of the pharmaceutical unit.

### Claim 28 (depends on 26)

The method according to claim 26, wherein an outer shell layer is composed of a hydrophobic material.

### Claim 29

A pharmaceutical dosage form, comprising:
an unfolding member comprising at least one elastic portion configured such that the unfolding member is in a contracted shape under the action of a constraint force, and returns to an unfolding shape when the constraint force is withdrawn; and
a retaining member surrounded the unfolding member and applying the constraint force to the unfolding member to enable the unfolding member to retain the contracted shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the unfolding member when the water-soluble material is dissolved, thereby allowing the unfolding member to at least partially unfold.

### Claim 30 (depends on 29)

The pharmaceutical dosage form according to claim 29, wherein the retaining member comprises a first portion and a second portion, the unfolding member is connected to the first portion, the second portion comprises a water-soluble material, and the retaining member removes the constraint force from the unfolding member when the water-soluble material of the second portion is dissolved, thereby allowing the unfolding member to at least partially unfold.

### Claim 31 (depends on 30)

The pharmaceutical dosage form according to claim 30, wherein the first portion comprises a first drug and the second portion comprises a second drug.

### Claim 32 (depends on 31)

The pharmaceutical dosage form according to claim 31, wherein the first portion comprises at least one compartment, and the first drug is disposed in the compartment.

### Claim 33 (depends on 30)

The pharmaceutical dosage form according to claim 30, wherein the unfolding member comprises a first portion and a second portion, and the first portion of the unfolding member has a dissolution rate in gastric juice less than the second portion of the retaining member in gastric juice.

### Claim 34 (depends on 33)

The pharmaceutical dosage form according to claim 33, wherein the first portion of the unfolding member comprises a drug.

### Claim 35 (depends on 33)

The pharmaceutical dosage form according to claim 33, wherein the unfolding member further comprises a third portion, wherein the first portion of the unfolding member is connected to the second portion of the unfolding member by the third portion of the unfolding member, and the first portion of the unfolding member is disconnected from the second portion when the third portion is dissolved.

### Claim 36 (depends on 35)

The pharmaceutical dosage form according to claim 35, wherein the second portion and the third portion of the unfolding member comprise a hydrophobic material and an enteric material.

### Claim 37 (depends on 33)

The pharmaceutical dosage form according to claim 33, wherein the first portion of the unfolding member substantially extends along a first direction, the second portion of the unfolding member substantially extends along a second direction, and the first portion and the second portion of the unfolding member are cross-connected to each other.

### Claim 38 (depends on 37)

The pharmaceutical dosage form according to claim 37, wherein the first portion of the unfolding member comprises at least one internal compartment, wherein a drug is disposed in the internal compartment.

### Claim 39 (depends on 29)

The pharmaceutical dosage form according to claim 29, wherein the elastic portion of the unfolding member is configured to substantially extend along a plane when the unfolding member is in a contracted configuration.

### Claim 40 (depends on 29)

The pharmaceutical dosage form according to claim 29, wherein the pharmaceutical dosage form has a length greater than or equal to 16 mm at least along one direction when the water-soluble material of the retaining member is at least partially dissolved.

### Claim 41 (depends on 29)

The pharmaceutical dosage form according to claim 29, wherein the unfolding member is configured to fully unfold within at least 10 min after entering gastric juice.

### Claim 42

A method for preparing a pharmaceutical dosage form using a three-dimensional printing process, comprising:
printing an unfolding member comprising at least one elastic portion configured such that the unfolding member is in a contracted shape under the action of a constraint force, and returns to an unfolding shape when the constraint force is withdrawn;
applying the constraint force to the unfolding member to enable the unfolding member to retain the contracted shape; and
printing a retaining member to retain the constraint force on the unfolding member by the retaining member to enable the unfolding member to retain the contracted shape;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the unfolding member when the water-soluble material is dissolved, thereby allowing the unfolding member to at least partially unfold.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the retaining member comprises a first portion and a second portion, and the method further comprises:
printing a first portion of the retaining member after printing the unfolding member, such that the unfolding member is connected to the first portion of the retaining member; and
applying the constraint force to the unfolding member by the first portion of the retaining member to enable the unfolding member to retain the contracted shape.

### Claim 44 (depends on 43)

The method according to claim 43, further comprising:
printing a second portion of the retaining member, wherein the second portion comprises a water-soluble material, and the retaining member removes the constraint force from the unfolding member when the water-soluble material of the second portion is dissolved, thereby allowing the unfolding member to at least partially unfold.

### Claim 45

A method for preparing a pharmaceutical dosage form using a three-dimensional printing process, comprising:
printing a retaining member; and
printing an unfolding member under the action of a constraint force of the retaining member within a range surrounded by the retaining member, such that the unfolding member is connected to the retaining member, wherein the unfolding member comprises at least one elastic portion configured to enable the unfolding member to at least partially unfold when the constraint force applied by the retaining member is removed;
wherein the retaining member comprises a water-soluble material, and the retaining member is configured to remove the constraint force from the unfolding member when the water-soluble material is dissolved, thereby allowing the unfolding member to at least partially unfold.
